S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer
Gastric Cancer
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring stage III gastric cancer, adenocarcinoma of the stomach
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed gastric adenocarcinoma, including type II or type III adenocarcinoma of the esophagogastric junction Stage III disease T3 or T4 and/or N2 No stage IV disease Helical CT scan and laparoscopic staging required Potentially resectable disease PATIENT CHARACTERISTICS: Age 20 and over Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic WBC ≥ 4,000/mm³, but < 12,000/mm³ Granulocyte count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Hepatic AST and ALT ≤ 2.5 times upper limit of normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine clearance ≥ 50 mL/min Pulmonary Arterial oxygen pressure (PaO_2) ≥ 70 mm Hg on room air Other Able to take oral medications PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy for gastric cancer Endocrine therapy Not specified Radiotherapy No prior radiotherapy for gastric cancer Surgery No prior surgery for gastric cancer Other No other prior therapy for gastric cancer
Sites / Locations
- Yamato Municipal Hospital
- Shimane Prefectural Central Hospital
- Fukui Red Cross Hospital
- Kyoto University Hospital
- National Hospital Organization - Kyoto Medical Center
- Kitano Hospital